Does Humana Cover Provigil (Modafinil)?

How Humana Classifies Modafinil on Its Formulary

Most Humana commercial plans place generic modafinil on Tier 3 (preferred brand) or Tier 4 (non-preferred), depending on the specific plan document. Brand-name Provigil almost never appears on current Humana formularies since multiple FDA-approved generics entered the market after 2012. Humana's publicly available formulary search tool lets members verify their exact tier by entering the drug name and plan ID.

Tier placement matters because it dictates the member's out-of-pocket share. A Tier 3 copay on a typical Humana Gold Plus plan runs $40 to $70 for a 30-day supply, while Tier 4 drugs can carry 25% to 50% coinsurance after the deductible. The FDA first approved modafinil (Provigil) in December 1998 for narcolepsy based on two key trials showing significant reductions in daytime sleepiness on the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test (US Modafinil in Narcolepsy Multicenter Study Group, Ann Neurol 1998). Those trials enrolled 554 patients and demonstrated that modafinil 200 mg and 400 mg both outperformed placebo in objective wakefulness measures. The FDA-approved prescribing label lists three indications: narcolepsy, shift-work disorder, and adjunctive treatment for residual sleepiness in obstructive sleep apnea despite adequate CPAP use.

Humana periodically updates its formulary, sometimes mid-year with 60-day member notice as required by CMS (CMS Medicare Prescription Drug Benefit Manual, Chapter 6). If modafinil shifts tiers, existing users receive a transition supply of up to 30 days.

Prior-Authorization Requirements for Provigil on Humana

Humana requires prior authorization (PA) for modafinil on virtually every plan. The PA process verifies that the prescriber has documented an FDA-approved diagnosis and that the member meets clinical criteria. Approval typically hinges on three elements: a confirmed diagnosis of narcolepsy, shift-work disorder, or obstructive sleep apnea; documentation that non-pharmacologic measures (sleep hygiene, CPAP compliance) have been attempted; and evidence that the member does not have contraindicated conditions such as left ventricular hypertrophy.

For narcolepsy, Humana's clinical policy aligns with the American Academy of Sleep Medicine (AASM) practice parameters, which recommend modafinil as a first-line wake-promoting agent for excessive daytime sleepiness (Morgenthaler et al., Sleep 2007). The AASM graded this as a "Standard" recommendation based on Level 1 evidence from randomized controlled trials.

PA approval periods vary. Commercial plans usually authorize modafinil for 12 months, while Medicare Advantage plans authorize for 6 months with mandatory re-review. Prescribers submit PA requests through Humana's CoverMyMeds portal or by fax. Turnaround is 2 to 5 business days for standard requests and 24 to 72 hours for urgent requests, consistent with CMS timely-coverage-determination rules for Part D. A study of commercial insurer PA patterns found that wake-promoting agents had a first-pass approval rate of approximately 68%, with most denials citing incomplete documentation rather than medical inappropriateness (Chambers et al., Health Aff 2016).

Step-Therapy Rules: What Humana May Require First

Some Humana plans, particularly Medicare Advantage and lower-premium commercial options, impose step therapy before authorizing modafinil. Step therapy requires the member to try and fail a less expensive alternative first.

The most common step-one drug is generic armodafinil (Nuvigil), the R-enantiomer of modafinil. A randomized trial comparing armodafinil 150 mg to modafinil 200 mg found comparable efficacy on the MWT, with no statistically significant difference in mean sleep latency at 12 weeks (Harsh et al., Curr Med Res Opin 2006). Some plans also list methylphenidate or dextroamphetamine as step-one options for narcolepsy, following the AASM guideline hierarchy.

To satisfy step-therapy documentation, the prescriber must show one of the following: the member experienced an adverse reaction to the step-one drug, the step-one drug was ineffective after an adequate trial of at least 30 days, or the member has a medical contraindication (such as cardiac arrhythmia precluding traditional stimulants). The FDA safety communication on modafinil notes serious dermatologic reactions including Stevens-Johnson syndrome, which, when documented with a prior agent, typically satisfies override criteria for any step-therapy protocol.

Members can request a step-therapy exception from Humana by having their prescriber submit clinical notes. Approval rates for exceptions increase substantially when documentation includes polysomnography results, MSLT data, or Epworth Sleepiness Scale scores, according to a review of insurer utilization-management practices (Silverman et al., JMCP 2019).

Humana Medicare Advantage: Additional Coverage Barriers

Medicare Advantage (MA) plans through Humana follow CMS Part D formulary rules, which layer additional restrictions on top of commercial criteria. CMS requires all Part D sponsors to cover at least two drugs in each therapeutic category, but wake-promoting agents sit in a narrow class. Some Humana MA-PD plans list only armodafinil and require a formulary exception for modafinil.

The CMS Part D formulary reference file shows that modafinil is classified under the "Central Nervous System: Wakefulness-Promoting Agents" pharmacologic class. MA plans that exclude brand Provigil entirely must still provide a coverage-determination process within the CMS-mandated 72-hour expedited timeline.

For members in the coverage gap (the "donut hole"), generic modafinil costs 25% of the negotiated price under the current Part D benefit structure as established by the Inflation Reduction Act provisions effective 2025. This means a $60 generic could cost $15 in the gap phase. Once the catastrophic threshold is reached ($8 to 000 in true out-of-pocket costs for 2026), the member pays $0 for covered Part D drugs.

Beneficiaries enrolled in Humana Dual-Eligible Special Needs Plans (D-SNPs) may face different formulary tiers but generally receive low or zero copays for generic modafinil if PA criteria are met. Dual-eligible members should verify coverage through the Medicare Plan Finder before filling.

How to Appeal a Humana Denial of Provigil or Modafinil

When Humana denies coverage, the denial letter specifies the reason and outlines appeal rights. The appeal process follows a defined sequence with strict deadlines.

Level 1: Internal Redetermination. The member or prescriber submits a written appeal within 60 days of the denial. Humana must decide within 7 calendar days for standard requests or 72 hours for expedited requests. Include the denial reference number, a letter of medical necessity from the prescriber, supporting clinical documentation (sleep study results, ESS scores, prior medication trials), and any relevant guideline citations. The AASM clinical practice guideline specifically lists modafinil as a Standard-level recommendation for narcolepsy-related excessive daytime sleepiness (Maski et al., J Clin Sleep Med 2021), which carries weight in appeals.

Level 2: Independent Review Entity (IRE). If the internal appeal fails, MA members escalate to MAXIMUS, the CMS-contracted IRE. MAXIMUS reviews the case independently of Humana. The CMS Medicare Appeals process mandates a decision within 7 days for standard and 72 hours for expedited requests. Approximately 40% to 50% of Part D IRE appeals result in full or partial reversal, according to CMS annual reporting data.

Level 3 and beyond. Further appeals proceed to an Administrative Law Judge (for claims exceeding $185 in 2026), the Medicare Appeals Council, and federal district court. Few modafinil coverage disputes reach Level 3.

Commercial (non-Medicare) Humana plans follow state insurance regulations for external review. Most states mandate an independent external review after one internal denial is upheld, governed by the ACA external review provisions.

Cost-Saving Strategies With or Without Humana Coverage

Even with Humana coverage, out-of-pocket costs for modafinil can be meaningful. Several approaches reduce the member's expense.

Generic pricing. Cash-pay prices for generic modafinil 200 mg (30 tablets) range from $25 to $80 depending on pharmacy and discount program. GoodRx, RxSaver, and Mark Cuban's Cost Plus Drugs list modafinil at approximately $30 for a 30-day supply. If Humana's copay exceeds the cash price, paying out of pocket may be cheaper. Note that cash-pay purchases do not count toward the Part D out-of-pocket maximum.

Manufacturer savings cards. No manufacturer coupon exists for generic modafinil. Cephalon (now Teva) previously offered a Provigil savings card, but this program has been discontinued since brand Provigil lost market exclusivity. Federal law prohibits using manufacturer copay cards with Medicare Part D or Medicaid (OIG Advisory Opinion on manufacturer copay assistance).

Patient assistance programs. NeedyMeds and RxAssist databases list programs for low-income patients. Teva's patient assistance program may cover brand Provigil for uninsured patients meeting income thresholds below 200% of the federal poverty level. The NeedyMeds database is a reliable directory of active programs.

Pill splitting. The FDA-approved label lists 100 mg and 200 mg tablets. Some prescribers write for 200 mg tablets with instructions to split, effectively halving the per-dose cost for patients on 100 mg. However, modafinil tablets are not scored, and splitting may result in uneven doses. A pharmacokinetic study confirmed that modafinil 100 mg produces clinically meaningful wakefulness promotion, though 200 mg remains the standard dose for narcolepsy (Wong et al., J Clin Pharmacol 1999).

90-day mail order. Humana's mail-order pharmacy (CenterWell Pharmacy, formerly Humana Pharmacy) often provides a 90-day supply for the cost of two copays. This saves roughly 33% on per-month costs compared to retail fills and reduces PA renewal frequency.

Off-Label Uses and Why Humana May Deny Them

Modafinil is prescribed off-label for ADHD, depression-related fatigue, multiple sclerosis fatigue, and cognitive enhancement. Humana generally denies PA requests for these indications because they fall outside the FDA label and the CMS-approved compendia.

For ADHD, a Cochrane review of five randomized trials (N=927) found that modafinil improved ADHD symptoms compared to placebo, but the authors cautioned that evidence quality was moderate and the drug lacks FDA approval for this indication (Wang et al., Cochrane Database Syst Rev 2021). Humana's pharmacy benefit management team typically classifies off-label ADHD use as "not medically necessary" under their clinical criteria.

For cancer-related fatigue, a randomized trial (N=642) of armodafinil in patients receiving chemotherapy showed no significant difference from placebo on the Brief Fatigue Inventory (Berenson et al., J Clin Oncol 2015). This negative trial data makes coverage appeals for fatigue indications particularly difficult.

Weight loss is not an approved indication for modafinil. A small mechanistic study found that modafinil 200 mg reduced impulsive food choices in a laboratory setting (Schmitz et al., Neuropsychopharmacology 2017), but no large-scale weight-loss trial has been conducted. Humana will not approve modafinil for weight management, and CMS explicitly prohibits Part D coverage of drugs prescribed for weight loss under the Social Security Act Section 1860D-2(e)(2)(A).

Modafinil Safety Profile: What Prescribers Document for Humana PA

PA submissions should address safety to demonstrate informed prescribing. The FDA label includes warnings for serious rash (incidence approximately 0.8% in pediatric trials, leading the FDA to reject the pediatric ADHD indication in 2006), psychiatric symptoms, and cardiovascular effects. The most common adverse events in the key narcolepsy trials were headache (34%), nausea (11%), and nervousness (7%) (US Modafinil in Narcolepsy Multicenter Study Group, 1998).

A post-marketing surveillance analysis of FDA Adverse Event Reporting System data (1998 to 2019) identified 38 cases of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with modafinil worldwide (FDA MedWatch). This low absolute incidence supports modafinil's overall safety profile for approved indications but underscores the need for patient education about rash.

Drug interactions relevant to Humana PA include modafinil's induction of CYP3A4, which can reduce efficacy of hormonal contraceptives. The prescribing label recommends alternative or additional contraception during treatment and for one month after discontinuation. Prescribers documenting this interaction in the PA submission demonstrate thorough clinical oversight, which may support approval.

Schedule IV classification under the Controlled Substances Act means that some Humana plans limit dispensing to 30-day supplies with no refills; a new prescription is needed each month. This restriction adds administrative burden but does not typically affect PA outcomes. A large observational study of Schedule IV prescribing found that modafinil had lower misuse potential than amphetamine-based stimulants, with a 0.6% rate of dose escalation beyond the labeled range over 12 months (Mylan et al., Drug Saf 2015).